Meeting
2022 ASCO Annual Meeting
Update on phase 1 study of tazemetostat, an enhancer of zeste homolog 2 inhibitor, in pediatric patients with relapsed or refractory integrase interactor 1–negative tumors.
Authors
Susan N. Chi
Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA
Susan N. Chi , Franck Bourdeaut , Michela Casanova , Lindsay Baker Kilburn , Darren R. Hargrave , Geoffrey Brian McCowage , Navin R. Pinto , Jay Yang , Raminder Chadha , Bhaskar Kahali , Coya Tapia , Karsten Nysom
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Pediatric Oncology
Track
Pediatric Oncology
Sub Track
Pediatric Solid Tumors
Clinical Trial Registration Number
NCT02601937
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 10040)
DOI
10.1200/JCO.2022.40.16_suppl.10040
Abstract #
10040
Poster Bd #
255
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Phase I study of tazemetostat, an enhancer of zeste homolog-2 inhibitor, in pediatric pts with relapsed/refractory integrase interactor 1-negative tumors.
First Author: Susan N. Chi
Poster
2024 ASCO Annual Meeting
TAZNI: A phase I/II combination trial of tazemetostat with nivolumab and ipilimumab for children with INI1-negative or SMARCA4-deficient tumors.
First Author: Joanna S. Yi
Poster
2016 ASCO Annual Meeting
A phase I study of the EZH2 inhibitor tazemetostat in pediatric subjects with relapsed or refractory INI1-negative tumors or synovial sarcoma.
First Author: Susan N. Chi
Poster
2020 ASCO Virtual Scientific Program
Safety and efficacy of tazemetostat, an enhancer of zeste-homolog 2 inhibitor, in patients with relapsed or refractory malignant mesothelioma.
First Author: Marjorie Glass Zauderer